Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

AlzeCure Pharma’s CEO Martin Jönsson.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

Limitless Potential: Winner of the Flemingsberg Science Award 2025

Young people in disadvantaged areas often face mental health challenges and a lack of support, which can lead to isolation and destructive choices. Limitless Potential, winner of the Flemingsberg Science Award IDEA 2025, has created a safe space where creativity and social entrepreneurship come together to support youth.

It’s official – Alfa Laval has opened its new premises in Flemingsberg!

The new 8,000 m² innovation center brings together 700 experts who push the boundaries of future solutions in energy, food, pharma and marine transport every day. An investment that truly shows how important Swedish industrial expertise, open collaborations and continued R&D are – not only for Alfa Laval, but for the whole of Europe.

50 years of life-changing therapies

On November 12 1975, the first allogeneic bone marrrow transplantation in Sweden was performed at Huddinge Hospital, here in Flemingsberg. On November 12 1975, the first allogeneic stem cell transplantation in Sweden was performed at Huddinge Hospital, here in Flemingsberg. From nuclear catastrophe the foundations of bone marrow transplantation had emerged, and with it, the birth of modern stem cell therapy — the same principles that today underpin cell and gene therapies and CAR-T treatments.